Jamal Alzubi

Freiburg, BW 79106, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Genotoxicity profiling reveals distinct platform-and cell type-specific effects in therapeutic gene editing for genetic hyperinflammation.

Genotoxicity profiling reveals distinct platform-and cell type-specific effects in therapeutic gene editing for genetic hyperinflammation.

Journal: Cell stem cell

Published: August 19, 2025

Engineering of Humanized PSMA-Directed CAR T Cells for Potent and Specific Elimination of Prostate Cancer Cells.

Engineering of Humanized PSMA-Directed CAR T Cells for Potent and Specific Elimination of Prostate Cancer Cells.

Journal: Cells

Published: August 02, 2025

Sustained and specific multiplexed immune checkpoint modulation in CAR T cells induced by targeted epigenome editing.

Sustained and specific multiplexed immune checkpoint modulation in CAR T cells induced by targeted epigenome editing.

Journal: Molecular therapy. Nucleic acids

Published: January 24, 2025

ID3 -depleted human induced pluripotent stem cell-derived neural stem/progenitor cells promote neurorepair.

ID3 -depleted human induced pluripotent stem cell-derived neural stem/progenitor cells promote neurorepair.

Journal: Neural regeneration research

Published: December 06, 2024

CRISPR-Cas12a for Highly Efficient and Marker-Free Targeted Integration in Human Pluripotent Stem Cells.

CRISPR-Cas12a for Highly Efficient and Marker-Free Targeted Integration in Human Pluripotent Stem Cells.

Journal: International journal of molecular sciences

Published: December 10, 2023

Cell-Based Models of 'Cytokine Release Syndrome' Endorse CD40L and Granulocyte-Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy.

Cell-Based Models of 'Cytokine Release Syndrome' Endorse CD40L and Granulocyte-Macrophage Colony-Stimulating Factor Knockout in Chimeric Antigen Receptor T Cells as Mitigation Strategy.

Journal: Cells

Published: September 22, 2023

CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells.

CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells.

Journal: Nature communications

Published: January 17, 2023

CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.

CRISPR-Cas9 based gene editing of the immune checkpoint NKG2A enhances NK cell mediated cytotoxicity against multiple myeloma.

Journal: Oncoimmunology

Published: June 13, 2022

The potential of CAR T cell therapy for prostate cancer.

The potential of CAR T cell therapy for prostate cancer.

Journal: Nature reviews. Urology

Published: May 27, 2021

Automated generation of gene-edited CAR T cells at clinical scale.

Automated generation of gene-edited CAR T cells at clinical scale.

Journal: Molecular therapy. Methods & clinical development

Published: October 27, 2020

Modeling MyD88 Deficiency In Vitro Provides New Insights in Its Function.

Modeling MyD88 Deficiency In Vitro Provides New Insights in Its Function.

Journal: Frontiers in immunology

Published: September 21, 2020

Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells.

Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells.

Journal: Gene therapy

Published: July 07, 2020

Showing 1-12 of 20

Last Updated: 09/26/2026